Zobrazeno 1 - 10
of 15
pro vyhledávání: '"K. Zierau"'
Publikováno v:
Zentralblatt für Chirurgie. 135:535-540
BACKGROUND: There are a number of effective substances available for palliative treatment of colorectal cancer, contributing to a considerable extension of the median survival time either purely medically or by increasing the chance of secondary rese
Autor:
D Jechorek, Ann Kristin Geers, Karsten Ridwelski, K. Zierau, Florian Dittmar, Patrick Stuebs, Jana Lessel, J. Fahlke
Publikováno v:
Journal of Clinical Oncology. 35:e15566-e15566
e15566 Background: The aim of this study was to determine whether overexpression of c-MET or HER2 had an effect on the clinical-pathological parameters and / or the prognosis of gastric carcinoma, as well as a direct correlation among those parameter
Autor:
Hans Lippert, K. Zierau, E. Kettner, P. Habermann, P Stübs, Benjamin Garlipp, J. Fahlke, T. Krause
Publikováno v:
Zeitschrift für Gastroenterologie. 49
Publikováno v:
Zentralblatt fur Chirurgie. 135(6)
There are a number of effective substances available for palliative treatment of colorectal cancer, contributing to a considerable extension of the median survival time either purely medically or by increasing the chance of secondary resectability th
Autor:
Ulrich Halm, Patrick Stuebs, Karsten Ridwelski, Carl Meissner, Christoph Kahl, Ronny Otto, Walter Asperger, J. Fahlke, Tobias Heina, K. Zierau, Matthias Krueger, Hendrik Kroening
Publikováno v:
Journal of Clinical Oncology. 33:4061-4061
4061 Background: Perioperative chemotherapy is standard of care in locally advanced gastroesophageal cancer (GEC included adenocarcinoma of gastroesophageal junction -GEJ- and gastric adenocarcinom...
Autor:
Hans Lippert, K. Zierau, Patrick Stuebs, Benjamin Garlipp, K. Schuette, Joerg Fahlke, P. Habermann
Publikováno v:
Journal of Clinical Oncology. 30:346-346
346 Background: Treatment of advanced CCC remains difficult. Sophisticated therapy of individual locations is essential due to differing biological characteristics. Apart from recent systemic therapeutic approaches, combined treatments using, among o
Autor:
Benjamin Garlipp, Hans Lippert, J. Fahlke, P. Habermann, Patrick Stuebs, K. Zierau, K. Schuette, T. Krause
Publikováno v:
Journal of Clinical Oncology. 29:e14587-e14587
e14587 Background: Multimodal treatment of the advanced gastric carcinoma is associated with an improved oncological outcome. There is a chance for improved time of survival for a selected group of...
Autor:
K. Zierau, Karsten Ridwelski, Patrick Stuebs, Hans Lippert, J. Fahlke, P. Habermann, E. Kettner, K. Schuette
Publikováno v:
Journal of Clinical Oncology. 28:e14572-e14572
e14572 Background: Comparison of first-line-treatment based on gemcitabine of inoperable and/or metastasized pancreatic cancer regarding effectiveness and feasibility. Methods: A total of 69 patien...
Autor:
Karsten Ridwelski, H. Kroehning, K. Zierau, Patrick Stuebs, A. Florschuetz, Hans Lippert, J. Fahlke, M. Leithaeuser, E. Kettner
Publikováno v:
Journal of Clinical Oncology. 27:e15592-e15592
e15592 Background: Based on promising published data, this multicenter, phase II study was initiated to investigate a combined treatment using DC and cetuximab in the first-line setting for patients with gastric cancer. Methods: Patients aged 18–75
Autor:
Hans Lippert, Martina Stauch, K. Zierau, M. Assmann, E. Kettner, U. Keilholz, Karsten Ridwelski, D. Quietzsch, C. Schmidt, J. Fahlke
Publikováno v:
Journal of Clinical Oncology. 26:4512-4512
4512 Background: Based on promising phase II studies, this randomized, multicenter phase III study compared DC with a commonly used regimen, FLC. Methods: Patients (pts) aged 18–75 years with stage III (T4, nonresectable) or IV gastric cancer, Karn